$38.19
0.040.10%
At Close: -
$37.00
-1.19-3.12%
After Hours: 6:38 PM EDT
15 minutes delayed
Comments
Loading...
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Calliditas Therapeutics (NASDAQ:CALT) Stock, Analyst Ratings, Price Targets, Forecasts
Calliditas Therapeutics AB has a consensus price target of $37.5 based on the ratings of 6 analysts. The high is $50 issued by HC Wainwright & Co. on October 16, 2023. The low is $18 issued by Guggenheim on August 18, 2023. The 3 most-recent analyst ratings were released by Citigroup, Jefferies, and Stifel on May 31, 2024, May 28, 2024, and May 28, 2024, respectively. With an average price target of $39.33 between Citigroup, Jefferies, and Stifel, there's an implied 6.31% upside for Calliditas Therapeutics AB from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Citigroup
Jefferies
Stifel
HC Wainwright & Co.
HC Wainwright & Co.
1calculated from analyst ratings
Analyst Ratings for Calliditas Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/31/2024 | Buy Now | 5.41% | Citigroup | Yigal Nochomovitz | → $39 | Downgrade | Buy → Neutral | Get Alert |
| 05/28/2024 | Buy Now | 5.41% | Jefferies | Maury Raycroft | $58 → $39 | Downgrade | Buy → Hold | Get Alert |
| 05/28/2024 | Buy Now | 8.11% | Stifel | Annabel Samimy | $55 → $40 | Downgrade | Buy → Hold | Get Alert |
| 05/28/2024 | Buy Now | 5.41% | HC Wainwright & Co. | Arthur He | → $39 | Downgrade | Buy → Neutral | Get Alert |
| 05/24/2024 | Buy Now | 21.62% | HC Wainwright & Co. | Arthur He | $50 → $45 | Maintains | Buy | Get Alert |
| 02/22/2024 | Buy Now | 35.14% | HC Wainwright & Co. | Arthur He | → $50 | Reiterates | Buy → Buy | Get Alert |
| 11/27/2023 | Buy Now | 35.14% | HC Wainwright & Co. | Arthur He | → $50 | Reiterates | Buy → Buy | Get Alert |
| 10/16/2023 | Buy Now | 35.14% | HC Wainwright & Co. | Edwin Zhang | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 08/21/2023 | Buy Now | 35.14% | HC Wainwright & Co. | Edwin Zhang | → $50 | Reiterates | Buy → Buy | Get Alert |
| 08/18/2023 | Buy Now | -51.35% | Guggenheim | Vamil Divan | $21 → $18 | Maintains | Neutral | Get Alert |
| 06/20/2023 | Buy Now | 62.16% | HC Wainwright & Co. | Edwin Zhang | → $60 | Initiates | → Buy | Get Alert |
| 03/01/2023 | Buy Now | -51.35% | Guggenheim | Vamil Divan | → $18 | Initiates | → Neutral | Get Alert |
| 02/24/2023 | Buy Now | 113.51% | Citigroup | Yigal Nochomovitz | $76 → $79 | Maintains | Buy | Get Alert |
| 12/20/2021 | Buy Now | 67.57% | HC Wainwright & Co. | Edwin Zhang | — | Maintains | Buy | Get Alert |
FAQ
What is the target price for Calliditas Therapeutics (CALT) stock?
The latest price target for Calliditas Therapeutics (NASDAQ:CALT) was reported by Citigroup on May 31, 2024. The analyst firm set a price target for $39.00 expecting CALT to rise to within 12 months (a possible 5.41% upside). 10 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Calliditas Therapeutics (CALT)?
The latest analyst rating for Calliditas Therapeutics (NASDAQ:CALT) was provided by Citigroup, and Calliditas Therapeutics downgraded their neutral rating.
When was the last upgrade for Calliditas Therapeutics (CALT)?
There is no last upgrade for Calliditas Therapeutics
When was the last downgrade for Calliditas Therapeutics (CALT)?
The last downgrade for Calliditas Therapeutics AB happened on May 31, 2024 when Citigroup changed their price target from N/A to $39 for Calliditas Therapeutics AB.
When is the next analyst rating going to be posted or updated for Calliditas Therapeutics (CALT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Calliditas Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Calliditas Therapeutics was filed on May 31, 2024 so you should expect the next rating to be made available sometime around May 31, 2025.
Is the Analyst Rating Calliditas Therapeutics (CALT) correct?
While ratings are subjective and will change, the latest Calliditas Therapeutics (CALT) rating was a downgraded with a price target of $0.00 to $39.00. The current price Calliditas Therapeutics (CALT) is trading at is $37.00, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.